Volume 28, Issue 2 (4-2025)
J Arak Uni Med Sci 2025, 28(2): 99-106 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Pouladi N, Javadi N, Didevar Tabrizi S. Studying of INV2nt-124A/G Polymorphism (rs5030772) in FASL Gene and Susceptibility to Thyroid Tumor in East Azerbaijan province. J Arak Uni Med Sci 2025; 28 (2) :99-106
URL: http://jams.arakmu.ac.ir/article-1-7941-en.html
URL: http://jams.arakmu.ac.ir/article-1-7941-en.html
1- Associate Professor, Department of Biology, School of Science, Azarbaijan Shahid Madani University, Tabriz, Iran , srna52@gmail.com
2- MSc Student, Department of Biology, School of Science, Azarbaijan Shahid Madani University, Tabriz, Iran
2- MSc Student, Department of Biology, School of Science, Azarbaijan Shahid Madani University, Tabriz, Iran
Abstract: (924 Views)
Background: Thyroid cancer is one of the most common types of endocrine malignancies. FASL is one of the most important apoptosis ligands expressed by tumor-infiltrating lymphocytes. This death ligand plays an important role in the elimination of cancer cells by inducing apoptosis in the Fas/FasL pathway, and its disruption induces tumorigenesis. This study investigated the association of the FASL gene polymorphism - INV2nt-124A/G (rs5030772) with the risk of thyroid cancer in the East Azerbaijan region.
Materials and Methods: In this case-control study, 115 patients with thyroid cancer and 125 healthy individuals without a family history of cancer from Tabriz city were studied. Five milliliters of peripheral blood were collected from each of these participants. Proteinase K method was used for DNA extraction and FASL gene polymorphism (rs5030772) was analyzed by ARMS-PCR technique. The results were analyzed using Javastat statistics package online software.
Results: The genotype frequencies of AA, AG and GG were 40.35%, 49.12% and 10.53% in patients and 41.6%, 52.8% and 5.6% in the control group, respectively. Genotypic and allelic frequencies did not show significant differences between the patient and control groups (p>0.05). By examining the clinicopathological characteristics of the patients, no significant relationship was seen between the clinical characteristics of the patients and the distribution of the genotypes of this polymorphism (p<0.05).
Conclusion: The results of this study indicate that the FASL gene polymorphism - INV2nt-124A/G (rs5030772) cannot be considered as a risk factor for thyroid cancer in the studied population in in East Azerbaijan province.
Materials and Methods: In this case-control study, 115 patients with thyroid cancer and 125 healthy individuals without a family history of cancer from Tabriz city were studied. Five milliliters of peripheral blood were collected from each of these participants. Proteinase K method was used for DNA extraction and FASL gene polymorphism (rs5030772) was analyzed by ARMS-PCR technique. The results were analyzed using Javastat statistics package online software.
Results: The genotype frequencies of AA, AG and GG were 40.35%, 49.12% and 10.53% in patients and 41.6%, 52.8% and 5.6% in the control group, respectively. Genotypic and allelic frequencies did not show significant differences between the patient and control groups (p>0.05). By examining the clinicopathological characteristics of the patients, no significant relationship was seen between the clinical characteristics of the patients and the distribution of the genotypes of this polymorphism (p<0.05).
Conclusion: The results of this study indicate that the FASL gene polymorphism - INV2nt-124A/G (rs5030772) cannot be considered as a risk factor for thyroid cancer in the studied population in in East Azerbaijan province.
Type of Study: Qualitative Study |
Subject:
Basic Sciences
Received: 2025/01/21 | Accepted: 2025/03/2
Received: 2025/01/21 | Accepted: 2025/03/2
References
1. Dhuli K, Medori MC, Donato K, Maltese PE, Tanzi B, Tezzele S, et al. Omics sciences and precision medicine in thyroid cancer. Clin Ter. 2023;174(Suppl 2(6)):11-20. pmid: 37994744 doi: 10.7417/CT.2023.2467
2. Peng X, Zhang K, Ma L, Xu J, Chang W. The role of long non-coding RNAs in thyroid cancer. Front Oncol. 2020;10:941. pmid: 32596158 doi: 10.3389/fonc.2020.00941
3. Leandro-García LJ, Landa I. Mechanistic insights of thyroid cancer progression. Endocrinology. 2023;164(9):bqad118. pmid: 37503738 doi: 10.1210/endocr/bqad118
4. Gielecińska A, Kciuk M, Kołat D, Kruczkowska W, Kontek R. Polymorphisms of DNA Repair Genes in Thyroid Cancer. Int J Mol Sci. 2024;25(11):5995. pmid: 38892180 doi: 10.3390/ijms25115995
5. Sudan J, Sharma S, Salgotra RK, Pandey RK, Neelam D, Singh R. Elucidating the process of SNPs identification in non-reference genome crops. J Biomol Struct Dyn. 2023;41(24):15682-90. pmid: 37021361 doi: 10.1080/07391102.2023.2194002
6. Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015;16(6):2129-44. pmid: 25824729 doi: 10.7314/apjcp.2015.16.6.2129.
7. Wang J, Cao Z, Wang P, Zhang X, Tang J, He Y, et al. Apoptotic extracellular vesicles ameliorate multiple myeloma by restoring fas-mediated apoptosis. ACS Nano. 2021;15(9):14360-72. pmid: 34506129 doi: 10.1021/acsnano.1c03517
8. Morana O, Wood W, Gregory CD. The apoptosis paradox in cancer. Int J Mol Sci. 2022;23(3):1328. pmid: 35163253 doi: 10.3390/ijms23031328
9. Chen R, Zou J, Zhong X, Li J, Kang R, Tang D. HMGB1 in the interplay between autophagy and apoptosis in cancer. Cancer Lett. 2024;581:216494. pmid: 38007142 doi: 10.1016/j.canlet.2023.216494
10. Abou Shousha S, Baheeg S, Ghoneim H, Zoheir M, Hemida M, Shahine Y. The effect of Fas/FasL pathway blocking on apoptosis and stemness within breast cancer tumor microenvironment (preclinical study). Breast Dis. 2023;42(1):163-76. pmid: 37334575 doi: 10.3233/BD-220077
11. Lagunas‐Rangel FA. Fas (CD95)/FasL (CD178) system during ageing. Cell Biol Int. 2023;47(8):1295-313. pmid: 37132427 doi: 10.1002/cbin.12032
12. Xu D, Wang B, Chen PP, Wang YZ, Miao NJ, Yin F, et al. c-Myc promotes tubular cell apoptosis in ischemia-reperfusion-induced renal injury by negatively regulating c-FLIP and enhancing FasL/Fas-mediated apoptosis pathway. Acta Pharmacol Sin. 2019;40(8):1058-66. pmid: 30593588 doi: 10.1038/s41401-018-0201-9
13. Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer–pilot study of 134 cases. PLoS One. 2013;8(1):e53075. pmid: 23326385 doi: 10.1371/journal.pone.0053075
14. Moudi B, Salimi S, Farajian Mashhadi F, Sandoughi M, Zakeri Z. Association of FAS and FAS ligand genes polymorphism and risk of systemic lupus erythematosus. ScientificWorldJournal. 2013; 2013:176741. pmid: 24348139 doi: 10.1155/2013/176741
15. Tahmasebi Fard Z. Evaluation of the effect of menopausal status and BMI on polymorphisms in Fas/Fas L and the risk of breast cancer. Clin Breast Cancer. 2024; 25(1):e56-e62. pmid: 39214844 doi: 10.1016/j.clbc.2024.07.006
16. Hajimirza Shafiesoltani P, Forouzesh F, Shabani M. The investigation of the role of Fas and FasL molecules in the extrinsic pathway of apoptosis as a target for cancer therapy in colorectal cancer [in Persian]. Clin Exc. 2020;10(3):1-17.
17. Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer–pilot study of 134 cases. PLoS One. 2013;8(1):e53075. pmid: 23326385 doi: 10.1371/journal.pone.0053075
18. Erdogan M, Karadeniz M, Berdeli A, Tamsel S, Ertan Y, Uluer H, et al. Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population. J Endocrinol Invest. 2007;30(5):411-6. pmid: 17598974 doi: 10.1007/BF03346319
19. Daripally S, Peddi K. Differential cancer risk and survival in Indian oral cancer patients with genic region FAS and FASL polymorphisms. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;133(3):315-25. pmid: 34753694 doi: 10.1016/j.oooo.2021.09.008
20. Poorheydar P, Hosseinpour Feizi M, Safaralizadeh R, Pouladi N, Ravanbakhsh Gavgani R. Study of FasL IVS2nt-124A/G polymorphism in breast cancer patients [in Persian]. J Shahid Sadoughi Univ Med Sci. 2017;25(4):279-86.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
